|Dr. Andre Choulika Ph.D.||Co-Founder, CEO & Director||879.06k||N/A||1965|
|Dr. David J. D. Sourdive Ph.D.||Director, Deputy CEO, Exec. VP of CMC and Manufacturing||580.28k||N/A||1967|
|Dr. Bing C. Wang M.B.A., Ph.D.||Chief Financial Officer||N/A||N/A||1977|
|Valerie Cros||Principal Financial Officer & Principal Accounting Officer||N/A||N/A||N/A|
|Mr. Jean Charles Epinat||Chief Technological Officer||N/A||N/A||N/A|
|Dr. Philippe Duchateau Ph.D.||Chief Scientific Officer||N/A||N/A||1963|
|Mr. Stephan Reynier M.Sc., MSc||Chief Regulatory & Pharmaceutical Compliance Officer||N/A||N/A||1969|
|Ms. Marie-Bleuenn Terrier||Gen. Counsel & Sec. of the Board of Directors||N/A||N/A||1982|
|Pascalyne Wilson||Director of Communications||N/A||N/A||N/A|
|Ms. Kyung Nam-Wortman||Exec. VP & Chief HR Officer||N/A||N/A||1970|
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis S.A.’s ISS governance QualityScore as of 31 July 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 10; Compensation: 8.